Last $1.38 USD
Change Today -0.05 / -3.50%
Volume 23.1K
VRML On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:39 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Open
$1.45
Previous Close
$1.43
Day High
$1.45
Day Low
$1.37
52 Week High
03/4/14 - $3.83
52 Week Low
12/9/14 - $1.20
Market Cap
49.7M
Average Volume 10 Days
43.7K
EPS TTM
$-0.49
Shares Outstanding
36.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women’s health. The company’s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

26 Employees
Last Reported Date: 03/31/14
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

vermillion inc (VRML) Key Developments

Vermillion, Inc. Announces Executive Changes

Vermillion, Inc. announced the next step in its expanded strategy to rebuild the company into a premier bio-analytics solutions provider with the naming of current Chief Operating Officer, Valerie Palmieri to President and Chief Executive Officer, while current Chairman of the Board and CEO James LaFrance will continue to serve as Chairman. These changes are effective January 1, 2015. As Chairman of the Board, he will continue to actively work with her and the management team to achieve the vision have crafted together.

Vermillion, Inc. Announces Board Appointments

Vermillion, Inc. announced the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the company's board of directors, bringing the total number of directors to eight, seven of whom are independent. Veronica Jordan, Ph.D. is an accomplished entrepreneur and international business leader.  David Schreiber has more than 30 years of corporate and consulting experience in the healthcare industry, particularly in the area of corporate finance, operations, and mergers and acquisitions.

Vermillion, Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Cash Flow Guidance for the Fourth Quarter of 2014; Provides Revenue Guidance for the Year 2015

Vermillion, Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. Total revenue in the third quarter of 2014 was $323,000, as compared to $330,000 in the same year-ago period. Net loss for the third quarter was $5,591,000 or $0.16 per share, as compared to a net loss of $2,314,000 or $0.10 per share in the year-ago quarter. Loss from operations was $5,589,000 against $2,317,000 a year ago. The company used $5.4 million in cash for operations in the third quarter of 2014. For the nine months ended September 30, 2014, net loss was $15,133,000 or $0.42 per diluted share as compared to a net loss of $7,002,000 or $0.36 per diluted share in the same year-ago period. Total revenue was $952,000 compared to $981,000 a year-ago. Loss from operations was $15,142,000 against $7,038,000 a year ago. The company expects to utilize $4.5 million to $5.0 million in cash in the fourth quarter of 2014 which will include certain non-recurring costs. The company plans to have substantial revenue growth in 2015 but expect to reach an inflection point the following year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $1.38 USD -0.05

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.12 USD -0.035
Health Discovery Corp $0.01 USD 0.00
Imperial Innovations Group PLC 442.50 GBp +2.50
MDxHealth €4.48 EUR +0.13
Miraculins Inc C$0.22 CAD +0.005
View Industry Companies
 

Industry Analysis

VRML

Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.4x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit www.vermillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.